Amicus Therapeutics – A Biopharmaceutical Firm Based in New Jersey

Amicus Therapeutics is a biopharmaceutical firm based in New Jersey, America. The firm went public in 2007 under the trading name, NASDAQ (Google Finance). The establishment of Amicus Therapeutics was financed by selected capital venture firms such as Radius Venture, New Enterprise Associates, and Canaan Partners. The organization focuses on the treatment of rare and orphan diseases, more so lysosomal storage disorders. The product development of the company is primarily based on CHART (Chaperone-Advanced Replacement Therapy), as well as enzyme replacement therapies.
In 2014, Amicus Therapeutics was noted as one of the companies that have the broadest portfolio of pharmacological chaperones small molecule in the pharmaceutical industry. Moreover, Amicus Therapeutics has a robust development pipeline for the treatment of various human genetic disease. For example, Amicus Therapeutics has a lead product known as migalastat. The product is a personalized medicine that is used for treating people with Fabry disease. Amicus Therapeutics is also working in collaboration with JCR Pharmaceutical and GlaxoSmithKline to explore coformulation with the recombinant alpha-galactosidase. However, the collaboration lasted for only three years.
Amicus does not have the manufacturing capability to produce its products. It relies on contracts from other companies for the manufacturing process. However, in 2008, the company expanded its operation. Apart from the normal research site in New Jersey, Amicus Therapeutics also has another research site in San Diego. Since its establishment, Amicus has been on the good side of the business. In 2010, Amicus Therapeutics received a grant worth $500000 from Michael Joseph Fox Foundation. The grant was meant to support the research study that was being conducted by Amicus in partnership with David Geffen Medical School. The company also received another grant worth $210300 from ADDF (Alzheimer’s Drug Discovery Foundation). Amicus Therapeutics used the grant to support its pre-clinical work. Also, in 2013, Amicus was able to have the necessary intellectual property and proprietary materials for the treatment of Pompe infection.

For more information visit:

| Twitter


Shampoo no more!

Shampoo is something that has been rooted into modern society’s hair care routine. It’s considered a fundamental thing to our daily lives. Truth be told, a lot of the time it contains harsh ingredients such as sulfates that do more damage than good to our hair. Conditioners are meant to make up for the damage that shampoo causes. It doesn’t have to be that way, though! We don’t need shampoo to get our hair clean.

WEN by Chaz Dean has a unique system that cleanses and conditions your hair without putting all the strain on it. Here’s how their simple Cleansing Conditioner works:

⦁ Get your hair wet, apply your Cleansing Conditioner. The thicker and longer your hair is, the more you’re going to want to apply.

⦁ Rub it in! Make sure to thoroughly get it to cover your scalp and hair. While it won’t lather up like sulfate filled products, water helps to spread it completely. For best results leave it in until the end of your shower.

⦁ When you’re ready to remove it, rinse your hair making sure all of it is out.

Simple, right? This product can also double as a leave-in conditioner. So why not apply some more in your damp hair?

Need Wen? Get this product at Sephora or the Guthy-Renker webstore.